ArchiveTraditional Chinese medicine (TCM) cosmetology is a discipline that uses TCM characteristic therapy under the guidance of TCM theory and Chinese aesthetic theory to correct or cover up diseases that damage beauty, so as to maintain the beauty of human form and body. In recent years, with the improvement of people's living standards, the demand for medical cosmetology is growing. TCM cosmetology has been widely used in modern cosmetics field such as whitening, freckle removal, anti-wrinkle, removing scar and weight loss because of its internal and external health, safety, economy, convenient and other advantages. This article took the modern application of TCM cosmetology as the main line, summarized the methods of TCM cosmetology and the existing clinical and basic research, in order to provide reference for the clinical application and further research of TCM cosmetology, and promote the construction and development of TCM cosmetology.
Treatment for hyperpigmented disorders often takes a long time to work and has poor patient compliance. Hyperpigmented skin diseases can be effectively treated by using a variety of lasers based on the principle of selective photothermolysis. Choosing the most appropriate type of laser depends on various factors, such as the melanin chromophore and its specific lesion location in the skin. This article reviewed the laser treatment on several hyperpigmentation disorders, such as nevoid lentigo, café-au-lait macules, Becker's nevus, intradermal nevus, nevus of Ota, melasma and post-inflammatory pigmentation etc, and compares the advantages of various lasers on the basis of published studies.
To strengthen the management of plastic and aesthetic surgery drugs in a third class hospital, and to explore the application effect of 9S management mode in the drug management of plastic and aesthetic surgery.
The management mode of plastic and aesthetic surgery drugs from January 2022 was compared with that before the application of this method. The scores of plastic and aesthetic surgery department in pharmacy and nursing department were compared before and after the implementation.
The management mode effectively promoted the improvement of drug management score in the department of plastic and aesthetic surgery. After the implementation, the drug expiration rate, drug mixing or misplacing rate, and drug storage method error rate were all lower than those before the implementation (P<0.05).
The application of 9S management mode in the management of plastic and aesthetic surgery drugs can effectively improve the level of drug management, and ensure the drug safety of patients.
The National Health Commission has issued the Guidelines for the Management of Clinical Comprehensive Evaluation (Trial) in July 2021 to provide guiding principles for the clinical comprehensive evaluation of drugs. Although the evaluation process, content and dimension are clearly defined in the guide, and the evidence information and evaluation quality control for evidence evaluation and application are emphasized, the detailed content and standards of quality control still need to be explored. This paper proposed a quality control system for clinical comprehensive evaluation of drugs in medical institutions from the perspectives of literature review, original research, economic research and investigation, hoping to provide references for the clinical application of drug comprehensive evaluation in medical institutions.
The systematic evaluation of pharmacoeconomic research has become one of the most valuable decision-making bases for national governments in macro health service policies, and plays an important role in medical decision-making, health resource allocation, new drug evaluation and many other aspects. This paper systematically introduces five steps of systematic evaluation of pharmacoeconomic research: (1. Forming research problems. 2. Literature retrieval and screening. 3. Data extraction, deviation risk and transferability evaluation. 4. Result report. 5. Discussion and interpretation of the results) and the currently advanced related methodologies, to help the inexperienced scholars and clinical practice guide developers prepare to write a systematic evaluation of pharmacoeconomic research.
The article discussed the methods for conducting systematic evaluation of pharmacoeconomics in China. Taking the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) reports and other relevant guidelines and recommended procedures and standards as reference, this paper explores its applicability in Chinese medical environment and its reference significance for systematic review of pharmacoeconomics in China. A standard systematic review of economic evaluation should include defining the research question, appraisal of applicability, appraisal of timeliness, and appraisal of methodology quality etc. The procedures recommended by ISPOR include research protocol design, literature search and screening, data extraction and reporting, which are worthy considering. However, the particularity of health care environment in local China should be taken into account in the specific application.
In 2022, The National Center for Comprehensive Assessment of Drug and Health Technology, in collaboration with relevant units, developed three technical guidelines for clinical comprehensive evaluation (for trial) of cardiovascular diseases, pediatric drugs and antineoplastic drugs, respectively. All guidelines mention that multi-criteria decision analysis (MCDA) can be used to rank the comprehensive value of drugs and help decision makers to make tradeoffs among multiple criteria to determine the best choice. At the same time, the guidelines mention, but do not go into depth, the weighting techniques that may be used in the MCDA process. This paper briefly composed the operational steps and characteristics of weighting techniques mentioned in the guidelines, hoping to promote the application of MCDA in the process of drugs clinical comprehensive evaluation in China and to form a MCDA method suitable for China's national conditions.
The article drew on the health technology assessment reports of the UK and Canada to provide suggestions for the development of comprehensive clinical evaluation of drugs in China. The completed full health technology assessment reports published by the United Kingdom (UK) and Canada from January 1, 2015 to August 4, 2022 were retrieved from the international HTA database on the official website of International Network of Agencies for Health Technology Assessment (INATA). Microsoft excel was used to extract the dimension information such as safety, effectiveness, cost-effectiveness and other key information in the HTA report, and descriptive statistical analysis was performed. A total of 325 HTA reports were finally included. Effectiveness, cost-effectiveness, and safety accounted for the highest proportions of evaluation dimensions, which were 250 (77%), 233 (72%), and 195 (60%), respectively. In addition, 153 (47%) reports assessed other dimensions. Among the 103 drug-related HTA reports, effectiveness, safety and cost-effectiveness accounted for the highest proportions of evaluation dimensions, which were 89 (86%), 83 (81%) and 73 (71%), respectively. In addition, 30 (29%) drug-related HTA reports assessed other dimensions. In conclusion, the comprehensive clinical evaluation of drugs in China can learn from the following characteristics of HTA reports of the UK and Canada to further improve its working mechanism: clarify the questions that need to be addressed in the comprehensive clinical evaluation of drugs, rationally select the dimensions of comprehensive clinical evaluation of drugs, carrying out comprehensive clinical evaluation of drugs starting from literature review, cost-effectiveness evaluation usually requires the team to carry out the original research to complete, budget impact analysis is only carried out with clear evidence users and necessity, multi-criteria decision analysis may not be an essential part of the HTA report itself, a comprehensive clinical evaluation of a drug can only answer limited questions.
To compare the clinical comprehensive value of gonadotropin-releasing hormone analogue (GnRHa) formulations (triptorelin versus leuprolide) in the treatment of central precocious puberty (CPP), in order to provide reference for clinical rational drug use and essential drug access decision-making.
According to the guidelines, a clinical comprehensive evaluation indicator system for GnRHa treatment of CPP was constructed through literature review, expert survey and expert argumentation. The weights of each indicator were determined by analytic hierarchy process. Systematic literature review, meta-analysis and other relevant data material analysis were utilized to perform qualitative and quantitative integrated analysis for each dimension and each indicator of the two GnRHa formulations.
Five first-level indicators, six second-level indicators and fourteen third-level indicators were constructed. The weights of safety, effectiveness, economy, appropriateness and accessibility were 0.59, 0.11, 0.12, 0.10, and 0.08, respectively. The overall score of triptorelin (63.68 points) was higher than that of leuprolide (56.38 points).
Compared with the leuprolide regimen for CPP treatment, triptorelin has obvious advantages in economy and effectiveness, and thus its clinical comprehensive value is higher than leuprolide regimen.
To investigate whether sesamin (SES) affects the human gastric mucosal epithelial cell injury induced by Helicobacter pylori (Hp) by regulating the expression of miR-204.
Human gastric mucosal epithelial cells were divided into control group, Hp group, Hp+SES low-dose (SES-L) group, Hp+SES medium dose (SES-M) group, Hp+SES high dose (SES-H) group, Hp+miR-204 simulant negative control (miR-NC) group, Hp+miR-204 simulant (miR-204) group, Hp+SES-H+miR-204 inhibitor negative control (anti miR-NC) group, and Hp+SES+miR-204 inhibitor (anti miR-204) group. Cell growth inhibition rate was detected by cell counting kit 8, cell apoptosis was detected by flow cytometry, the protein expression of cleaved caspase 3 and 9 were detected by western blot, lactate dehydrogenase (LDH) activity and interleukin-1β (IL-1β) and IL-8 level were detected by the kit, and reverse transcription quantitative polymerase chain reaction was used to detect miR-204 expression.
Compared with Hp group, the Hp+SES-L group, Hp+SES-M group and Hp+SES-H group had significant reductions in the growth inhibition rate, cell apoptosis rate, and the protein expression of cleaved-caspase 3 and 9 in gastric mucosal epithelial cells in a concentration-dependent manner (P<0.05). Compared with Hp group, the LDH activity, the levels of IL-1β and IL-8 in human gastric mucosal epithelial cells were decreased in a concentration- dependent manner in Hp+SES-L group, Hp+SES-M group and Hp+SES-H group (P<0.05). After miR-204 overexpression, the expression of miR-204 in human gastric mucosal epithelial cells in Hp+miR-204 group was higher than that in Hp+miR-NC group, but the growth inhibition rate, apoptosis rate, the protein expression of cleaved caspase-3, cleaved caspase-9, LDH activity, and IL-1β and IL-8 levels were decreased compared with Hp+miR-NC group (P<0.05). After interfering with the expression of miR-204, the expression of miR-204 in human gastric mucosal epithelial cells in Hp+SES+anti miR-204 group was lower than that in Hp+SES+anti miR-NC group, while the growth inhibition rate, apoptosis rate, the protein expression of cleaved-caspase3, cleaved-caspase 9, LDH activity, IL-1β and IL-8 were higher than those in Hp+SES+anti miR-NC group (P<0.05).
SES can increase Hp induced human gastric mucosal epithelial cells vitality and reduce apoptosis and inflammation by up regulating the expression of miR-204.
To explore the key active ingredients and molecular mechanisms of keluoxin in the treatment of diabetic nephropathy (DN) by network pharmacology and molecular docking methods.
The active constituents and their corresponding targets of keluoxin were obtained through the pharmacological analysis platform of traditional Chinese medicine. Disease targets related to DN were obtained by GeneCards and OMIM databases, and drug targets of DN were screened. Cytoscape software was used to map active ingredient-target network and protein-protein interaction network. Gene ontology and functional enrichment analysis of Kyoto gene and genome database were conducted on the target. Autodock Vina software was used to verify the molecular docking between the main active ingredients of keluoxin and the key targets.
Keluoxin can exert its therapeutic effect on DN by acting on 97 target genes through 57 active ingredients. There were 9 main active ingredients, which can regulate signaling pathway by influencing oxidative stress, inflammatory response, hypoxia response, metabolic regulation and cell apoptosis. Molecular docking results showed that quercetin, luteolin and calycoflavone had the strongest affinity to the key targets, which may be the core acting molecules in keluoxine.
The potential mechanism of keluoxin in the treatment of DN is multi-target and multi-pathway, among which quercetin, luteolin and calycoflavone may be the core molecules in keluoxin.
To analyze the effect of dapagliflozin combined with levosimendan in the treatment of elderly patients with heart failure with reduced ejection fraction (HFrEF).
A total of 144 elderly patients with HFrEF in our hospital from July 2019 to July 2022 were selected and randomly divided into the study group and the control group, with 72 cases in each group. The control group was given levosimendan, and the study group was given dapagliflozin on the basis of the control group. The treatment effects and adverse reactions of the two groups were compared. Myocardial microcirculation indexes [(total myocardial ischemia load, frequency and duration of ST segment decline)], oxidation/antioxidant balance index [malondialdehyde (MDA), superoxide dismutase (SOD), lipid peroxide (LPO), glutathione peroxidase (GSH-Px)] were detected before and after treatment. The both groups were followed up for 6 months and the readmission rate was counted.
The total effective rate of the study group was 95.83%, which was higher than 86.11% of the control group (P<0.05). After treatment, the total myocardial ischemia load, frequency and duration of ST segment decline, MDA and LPO in the two groups significantly decreased compared with those before treatment, and those in the study group was lower than those in the control group (P<0.05). After treatment serum SOD and GSH-Px in the two groups were higher than those before treatment, and those in the study group were higher than those in the control group (P<0.05). There was no statistically significant difference in adverse reactions between the two groups (8.33% vs 5.56%, P>0.05).
Dapagliflozin combined with levosimendan is effective, safe and reliable in the treatment of elderly HFrEF patients, which is helpful to correct the oxidation/antioxidant balance and improve myocardial microcirculation.
To investigate the effects of metoprolol combined with tirofiban in the treatment of acute myocardial infarction (AMI) and its effects on serum lipoprotein-associated phospholipase (Lp-PL) A2, growth differentiation factor (GDF)-15 and soluble ST2 protein (sST2).
A total 165 patients with AMI who received treatment in the department of cardiology of Yancheng third people's hospital from January 2020 to June 2022 were selected and divided into experimental group (n=83, metoprolol+tirofiban) and control group (n=82, metoprolol) by random number table method. Clinical efficacy, serum Lp-PLA2, GDF-15, sST2, cardiac output (CO), stroke volume (SV), left ventricular ejection fraction (LVEF), cardiovascular adverse events (CVAE) and incidence of adverse reactions were compared between the two groups.
After treatment, the total effective rate of experimental group was higher than that of control group (93.98% vs 82.93%), the difference was statistically significant (P<0.05). Serum Lp-PLA2, GDF-15 and sST2 levels in two groups were decreased over time, and the experimental group was lower than the control group, the difference was statistically significant (P<0.05). The levels of CO, SV and LVEF in both groups were increased over time, and the experimental group was higher than the control group, the difference was statistically significant (P<0.05). The reoccurrence of MI, angina pectoris, heart failure and its severity in experimental group were lower than those in control group, and the difference were statistically significant (P<0.05). There was no statistical significance in the occurrence of adverse reactions between the two groups (P>0.05).
Metoprolol combined with tirofiban is effective in AMI patients, which can effectively improve serum Lp-PLA2, GDF-15, sST2 and cardiac function.
To explore the influence of continuous analgesia with fascia iliaca compartment block (FICB) on postoperative pain and early rehabilitation after hip fracture surgery in the elderly.
A total of 103 elderly patients with hip fracture underwent surgical treatment in the Department of Anesthesiology, Luliang People's Hospital from August 2017 to August 2019 were selected and divided into observation group (n=52) and control group (n=51) by random number table method. Both groups were given general anesthesia, the control group was given postoperative intravenous analgesia, and the observation group was given FICB continuous analgesia. The visual analogue scale (VAS), serum cortisol (Cor), angiotensin (Ang) Ⅱ, activities of daily living (ADL) and Harris hip rating scale and complications were compared between the two groups at different time points.
The total excellent and good rate of the observation group was 94.23%, which was higher than that of the control group 80.39% (P<0.05). At 4 h and 12 h after surgery, VAS scores in both groups increased with time, and the observation group was lower than those of the control group (P<0.05). At 24 h and 48 h after surgery, VAS scores of both groups were decreased with time, and the observation group was lower than those of the control group (P<0.05). After surgery, the levels of Cor and AngⅡ in both groups were decreased with time, and the observation group were lower than those of the control group (P<0.05). Thirty days after surgery, ADL and Harris scores of both groups were increased with time, and the observation group were higher than those of the control group (P<0.05). The hospitalization time of the observation group was shorter than that in the control group, and the difference was significant (P<0.05). The total incidence of complications in the observation group was lower than that in the control group (7.69% vs 25.49%, P<0.05).
The application of FICB for continuous analgesia in elderly patients with hip fracture can help promote postoperative rehabilitation and effectively improve postoperative pain, with fewer complications.
To investigate the correlation between gene polymorphism of cyclophosphamide (CTX) metabolic enzyme and membranous nephropathy (MN), and to provide a basis for individualized drug administration.
The clinical data of 80 MN patients treated with CTX in the department of nephropathy, Shanghai Changzheng hospital from January 2021 to October 2022 were analyzed, and the metabolic enzyme genes of CTX (CYP2C19*2, CYP2C19*3, CYP3A5, GSTP1) were detected. The changes of 24 h urinary protein quantity, serum albumin, creatinine (Cr) and the adverse drug events were observed and analyzed when CTX was used and 1, 3, 6, and 12 months after treatment.
The frequency distributions of CYP2C19*2, CYP2C19*3, CYP3A5 and GSTP1 were consistent with Hardy-Weinberg equilibrium distribution. In CYP2C19*2 GA genotype carriers, there were significant difference in 24 h urinary protein, serum albumin and Cr levels compared with those before treatment (P<0.05). In CYP2C19*3 GG, GA and AA genotype carriers, there was no significant difference in 24 h urinary protein, serum albumin and Cr levels compared with those before treatment (P>0.05). In CYP3A5 AG genotype carriers, there was a significant difference in Cr level compared with that before treatment (P<0.05), but there was no significant difference in serum albumin and 24 h urinary protein quantification. In glutathione S-transferase pi-1 AA, AG and GG genotype carriers, there was no significant difference in 24 h urinary protein, serum albumin and Cr levels compared with those before treatment (P>0.05).
The gene polymorphism of CTX metabolic enzyme CYP2C19*2 may have a significant effect on the efficacy of MN, and the efficacy of GA genotype carriers is better. The Cr level in CYP3A5 AG genotype carriers is significantly reduced.
To retrospectively analyze the effects of different doses of rivaroxaban on renal function outcome and prognosis in elderly patients with atrial fibrillation (AF) combined with stable coronary artery disease (SCAD).
A total of 416 elderly (≥65 years old) AF-SCAD patients who received rivaroxaban treatment (≥3 months) in our hospital from January to December 2018 were retrospectively analyzed, and divided into low-dose group (<10 mg/d), conventional-dose group (10 - 15 mg/d) and high-dose group (20 mg/d) according to the initial dose. The primary effective end points of treatment included cardiovascular death, myocardial infarction, ischemic stroke/transient ischemic attack, pulmonary embolism and deep venous thrombosis of the lower extremities. The primary safety end points were bleeding events and acute kidney disease (AKD).
There were statistically significant differences in baseline creatinine clearance and medication time of rivaroxaban among the three groups (P<0.05). The incidence of AKD in the high-dose group was higher than that in the low-dose group during follow-up (P<0.05). Univariate and multivariate logistic regression analysis showed that after adjusting the time of administration of rivaroxaban and the initial serum creatinine clearance, rivaroxaban 20 mg/d was still an independent risk factor for AKD in patients with AF-SCAD (odds rate=3.579, 95% confidence interval: 1.879 -9.974), and also the independent risk factor for AKD in patients with baseline serum creatinine clearance of 50 - 79ml/min or ≥80ml/min (odds rate=6.876, 95% confidence interval: 2.647 - 14.652, odds rate=2.159, 95% confidence interval: 1.042 - 5.477). In addition, for patients with baseline serum creatinine clearance of 50 - 79ml/min, the conventional dose of rivaroxaban (10 - 15 mg/d) also increase the risk of AKD in patients with AF-SCAD (odds rate=1.254, 95% confidence interval: 1.001 - 1.959).
Rivaroxaban 20 mg/d can increases AKD risk in elderly patients with AF-SCAD and received percutaneous coronary intervention.
To evaluate the efficacy of osimertinib mesylate in the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) by Meta analysis.
The literature of randomized controlled trial (RCT) of osimertinib mesylate in the treatment of EGFR mutant NSCLC published in the well-known domestic and foreign databases from the establishment of the database to May 2022 were included, and RevMan5.2 software was used to perform meta-analysis on its effect.
A total of 7 articles were included, including 2 reports in Chinese and 5 reports in English, with a total of 2 591 patients. There were 1 385 cases in the experiment group treated with osimertinib mesylate and 1 206 cases in the control group treated with chemotherapy or gefitinib or erlotinib. The quality of the included articles was up to the standard. The literature on clinical benefit rate and total effective rate was heterogeneous (I2=62%, P=0.02; I2=65%, P=0.04). Random effects model analysis showed no significant difference (RR=0.08, 95%CI: -0.12 -0.14, P=0.159; RR=0.04, 95%CI: -0.02 - 0.11, P=0.136). There were no heterogeneity in progression free survival (PSF), overall survival (OS), survival, and median duration of remission (mDOR, I2=41%, P=0.26; I2=36%, P=0.31; I2=25%, P=0.63; I2=18%, P=0.72). The PSF, OS and mDOR in the experiment group were longer than those in the control group (WMD=4.38, 95%CI: 4.25 - 4.46, P<0.001; WMD=3.97, 95%CI: 3.82 - 4.09, P<0.001; WMD=3.36, 95%CI: 3.14~3.58, P<0.001), and the survival rate of the experiment group was higher than that of the control group (WMD=2.57, 95%CI: 2.25 - 2.7, P<0.001). There was no risk of publication bias.
Compared with chemotherapy or gefitinib or erlotinib, osimertinib mesylate can prolong PSF, OS, mDOR and improve survival rate in patients with EGFR mutant NSCLC.
Breast cancer is the first malignant tumor, which seriously threatens women's life and health. HER2-targeted therapies have experienced more than 20 years of development and are important biomarkers affecting the prognosis and treatment strategies of breast cancer. Current guidelines use the combined detection method IHC and ISH to detect HER2 expressions, status in breast cancer. There is a consensus that classifying the HER2-low in negative patients. Anti-HER2 drugs on the market include antibodies, small-molecule drugs and ADCs, which can be used for effective treatment of different expression of HER2. This article reviewed the different expression status of HER2 in breast cancer and the research progress of anti-HER2 drugs.